Evaluating the prognostic value of new cardiovascular biomarkers

Disease Markers

Volumn 26, Issue 5-6, 2009, Pages 199-207

  Wood, Angela M ^b   Greenland, Philip ^a,c  

^a University of Cambridge ^*  (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarkers; Cardiovascular risk; Prediction; Statistics

Indexed keywords

BIOLOGICAL MARKER;

CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MATHEMATICAL ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

EID: 70349915763     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2009-0631     Document Type: Review

References (56)

1. D.G. Altman and P. Royston, What do we mean by validating a prognostic model? Stat Med 19 (2000), 453-473.
2. P. Brindle, J. Emberson, F. Lampe, M. Walker, P. Whincup and S. Ebrahim, Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study, BMJ 327 (2003), 1267-1270.
3. M.D. Cabana, C.S. Rand, N.R. Powe, A.W. Wu, M.H. Wilson, P.A. Abboud and H.R. Rubin, Why don't physicians follow clinical practice guidelines? A framework for improvement, JAMA 282 (1999), 1458-1465.
4. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr. and E.J. Roccella, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA 289 (2003), 2560-2572.
5. N. Cook, Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M.J. Pencina et al., Statistics in Medicine, Stat Med 27 (2008), 191-195.
6. N.R. Cook, Use and misuse of the receiver operating characteristic curve in risk prediction, Circulation 115 (2007), 928-935. (Pubitemid 46294733)
7. N.R. Cook, J.E. Buring and P.M. Ridker, The effect of including C-reactive protein in cardiovascular risk prediction models for women, Ann Intern Med 145 (2006), 21-29. (Pubitemid 46780601)
8. R.B. D'Agostino Sr., S. Grundy, L.M. Sullivan and P. Wilson, CHD Risk Prediction Group, Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation, JAMA 286 (2001), 180-187.
9. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys and V. Gudnason, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med 350 (2004), 1387-1397.
10. R. Detrano, A.D. Guerci, J.J. Carr, D.E. Bild, G. Burke, A.R. Folsom, K. Liu, S. Shea, M. Szklo, D.A. Bluemke, D.H. O'Leary, R. Tracy, K. Watson, N.D. Wong and R.A. Kronmal, Coronary calcium as a predictor of coronary events in four racial or ethnic groups, N Engl J Med 358 (2008), 1336-1345.
11. B. Efron, The efficiency of logistic regression compared to normal discriminant analysis, J AmStat Assoc 70 (1975), 892-898.
12. A.R. Folsom, L.E. Chambless, C.M. Ballantyne, J. Coresh, G. Heiss, K.K. Wu, E. Boerwinkle, T.H. Mosley Jr., P. Sorlie, G. Diao and A.R. Sharrett, An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study, Arch Intern Med 166 (2006), 1368-1373.
13. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European guidelines on cardiovascular disease prevention in clinical practice: executive summary, Eur Heart J 28 (2007), 2375-2414.
14. J.P. Frolkis, S.J. Zyzanski, J.M. Schwartz and P.S. Suhan, Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines, Circulation 98 (1998), 851-855.
15. D.G. Fryback and J.R. Thornbury, The efficacy of diagnostic imaging, Med Decis Making 11 (1991), 88-94.
16. T.A. Gerds, T. Cai and M. Schumacher, The performance of risk prediction models, Biometrical Journal 50 (2008), 457-479.
17. R.E. Gerszten and T.J. Wang, The search for new cardiovascular biomarkers, Nature 451 (2008), 949-952.
18. M. Gonen and G. Heller, Concordance probability and discriminatory power in proportional hazards regression, Biometrika 92 (2005), 965-970.
19. P. Greenland, L. LaBree, S.P. Azen, T.M. Doherty and R.C. Detrano, Coronary artery calcium score combined with Fram ingham score for risk prediction in asymptomatic individuals, JAMA 291 (2004), 210-215. (Pubitemid 38082815)
20. F.E. Harrell Jr., R.M. Califf, D.B. Pryor, K.L. Lee and R.A. Rosati, Evaluating the yield of medical tests, JAMA 247 (1982), 2543-2546.
21. F.E. Harrell Jr., K.L. Lee and D.B. Mark, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med 15 (1996), 361-387.
22. J. Hippisley-Cox, C. Coupland, Y. Vinogradova, J. Robson and P. Brindle, Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study, Heart 94 (2008), 34-129
23. D.W. Hosmer and S. Lemeshow, Applied Logistic Regression, New York: Wiley, 1989, Section 5.2.2.
24. D.W. Hosmer, T. Hosmer, S. Le Cessie and S. Lemeshow, A comparison of goodness-of-fit tests for the logistic regression model, Stat Med 16 (1997), 965-980. (Pubitemid 27198985)
25. H. Janes, M.S. Pepe and W. Gu, Assessing the value of risk predictions by using risk stratification tables, Ann Intern Med 149 (2008), 751-760.
26. A.C. Justice, K.E. Covinsky and J.A. Berlin, Assessing the Generalizability of Prognostic Information, Ann Intern Med 130 (1999), 515-524.
27. S. Laurent, J. Cockcroft, L. Van Bortel, P. Boutouyrie, C. Giannattasio, D. Hayoz, B. Pannier, C. Vlachopoulos, I. Wilkinson and H. Struijker-Boudier, European Network for Non-invasive Investigation of Large Arteries, Expert consensus document on arterial stiffness: methodological issues and clinical applications, Eur Heart J 27 (2006), 2588-2605.
28. G.D. Lewis, A. Asnani and R.E. Gerszten, Application of metabolomics to cardiovascular biomarker and pathway discovery, J Am Coll Cardiol 52 (2008), 117-123.
29. J. Liu, Y. Hong, R.B. D'Agostino Sr., Z. Wu, W. Wang, J. Sun, P.W. Wilson, W.B. Kannel and D. Zhao, Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study, JAMA 291 (2004), 2591-2599.
30. P. McBride, H.G. Schrott, M.B. Plane, G. Underbakke and R.L. Brown, Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease, Arch Intern Med 158 (1998), 1238-1244.
31. D. McFadden, Conditional logit analysis of qualitative choice behavior, in: Frontiers in Economics, P. Zarembka, ed., NY: Academic Press, 1974.
32. K. McGeechan, P. Macaskill, L. Irwig, G. Liewand T.Y. Wong, Assessing New Biomarkers and Predictive Models for Use in Clinical Practice: A Clinician's Guide, Arch Intern Med 168 (2008), 2304-2310.
33. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 106 (2002), 3143-3421
34. N.P. Paynter, D.I. Chasman, J.E. Buring, D. Shiffman, N.R. Cook and P.M. Ridker, Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3, Ann Intern Med 150 (2009), 65-72.
35. T.A. Pearson, I. Laurora, H. Chu and S. Kafonek, The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals, Arch Intern Med 160 (2000), 459-467.
36. A. Peer, G. Falkensammer, H. Alber, A. Kroiss, A. Griesmacher, H. Ulmer, O. Pachinger and J. Mair, Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease, Heart 95 (2009), 297-303.
37. M.J. Pencina, A.R. D' Sr., A.R. D' Jr. and R.S. Vasan, Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond, Stat Med 27 (2007), 157-172.
38. M.S. Pepe, H. Janes, G. Longton, W. Leisenring and P. Newcomb, Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker, Am J Epidemiol 159 (2004), 882-890.
39. P.M. Ridker, J.E. Buring, N. Rifai and N.R. Cook, Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score, JAMA 297 (2007), 611-619. (Pubitemid 46257283)
40. P.M. Ridker, N.P. Paynter, N. Rifai, J.M. Gaziano and N.R. Cook, C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction, The Reynolds Risk Score for Men, Circulation 118 (2008), 2243-2251.
41. P. Royston and W. Sauerbrei, A new measure of prognostic separation in survival data, Stat Med 23 (2004), 723-748. (Pubitemid 38279510)
42. P. Royston, M.K. Parmar and R. Sylvester, Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer, Stat Med 23 (2004), 907-926.
43. M. Schemper, The explained variation in proportional hazards regression, Biometrika 77 (1990), 216-218.
44. M. Schemper and R. Henderson, Predictive accuracy and explained variation in Cox regression Biometrics 56 (2000), 249-255.
45. M. Schemper and J. Stare, Explained variation in survival analysis, Stat Med 15 (1996), 1999-2012.
46. S. Sheridan, M. Pignone and C. Mulrow, Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians, J Gen Intern Med 18 (2003), 1039-1052. (Pubitemid 38091400)
47. S.L. Sheridan and E. Crespo, Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature, BMC Health Serv Res 8 (2008), 60.
48. M.G. Shlipak, L.F. Fried, M. Cushman, T.A. Manolio, D. Peterson C. Stehman-Breen, A. Bleyer, A. Newman, D. Siscovick and B. Psaty, Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors, JAMA 293 (2005), 1737-1745. (Pubitemid 40491299)
49. The Fibrinogen Studies Collaboration, Measures to assess the prognostic ability of the stratified Cox proportional hazards model, Stat Med 28 (2009), 389-411.
50. A. Tonkin, P. Barter, J. Best, A. Boyden, J. Furler, K. Hossack, D. Sullivan, P. Thompson, M. Vale, C. Cooper, M. Robinson and E. Clune, National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management-2005, Heart Lung Circ 14 (2005), 275-291.
51. H. Vidula, L. Tian, K. Liu, M.H. Criqui, L. Ferrucci, W.H. Pearce, P. Greenland, D. Green, J. Tan, D.B. Garside, J. Guralnik, P.M. Ridker, N. Rifai and M.M. McDermott, Biomark ers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study, Ann Intern Med 148 (2008), 85-93.
52. N.J. Wald, A.K. Hackshaw and C.D. Frost, When can a risk factor be used as a worthwhile screening test? Br Med J 319 (1999), 1562-1565.
53. T.J. Wang, P. Gona, M.G. Larson, G.H. Tofler, D. Levy, C. Newton-Cheh, P.F. Jacques, N. Rifai, J. Selhub, S.J. Robins, E.J. Benjamin, R.B. D'Agostino and R.S. Vasan, Multiple biomarkers for the prediction of first major cardiovascular events and death, N Engl J Med 355 (2006), 2631-2639. (Pubitemid 44969122)
54. P.W.R. Wilson, M. Pencina, P. Jacques, J. Selhub, R. D'Agostino Sr. and C.J. O'Donnell, C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study, Circulation: Cardiovascular Quality and Outcomes 1 (2008), 92-97.
55. J.C. Wyatt and D.G. Altman, Commentary: Prognostic models: clinically useful or quickly forgotten? BMJ 311 (1995), 1539-1541.
56. B. Zethelius, L. Berglund, J. Sundström, E. Ingelsson, S. Basu, A. Larsson, P. Venge and J. Arnlöv, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes, N Engl J Med 358(20) (2008), 2107-2116.